Saltar al contenido
Merck

SML2223

Sigma-Aldrich

WAY-267464 dihydrochloride

≥98% (HPLC)

Sinónimos:

4-(3,5-Dihydroxy-benzyl)-piperazine-1-carboxylic acid 2-methyl-4-(3-methyl-4,10-dihydro-3H-2,3,4,9-tetraaza-benzo[f]azulene-9-carbonyl)-benzylamide dihydrochloride, N-[[4-[(4,10-Dihydro-1-methylpyrazolo[3,4-b][1,5]benzodiazepin-5(1H)-yl)carbonyl]-2-methylphenyl]methyl]-4-[(3,5-dihydroxyphenyl)methyl]-1-piperazinecarboxamide dihydrochloride, WAY 267,464 dihydrochloride, WAY 267464 dihydrochloride, WAY-267,464 dihydrochloride, WAY267464 dihydrochloride

Iniciar sesiónpara Ver la Fijación de precios por contrato y de la organización


About This Item

Fórmula empírica (notación de Hill):
C32H35N7O4 · 2HCl
Número de CAS:
Peso molecular:
654.59
MDL number:
UNSPSC Code:
12352200
NACRES:
NA.77

En este momento no podemos mostrarle ni los precios ni la disponibilidad

assay

≥98% (HPLC)

form

powder

storage condition

desiccated

color

white to beige

solubility

H2O: 2 mg/mL, clear

storage temp.

2-8°C

SMILES string

O=C(NCC1=CC=C(C=C1C)C(N2CC3=C(NC4=CC=CC=C24)N(N=C3)C)=O)N5CCN(CC5)CC6=CC(O)=CC(O)=C6

InChI

1S/C32H35N7O4.2ClH/c1-21-13-23(31(42)39-20-25-18-34-36(2)30(25)35-28-5-3-4-6-29(28)39)7-8-24(21)17-33-32(43)38-11-9-37(10-12-38)19-22-14-26(40)16-27(41)15-22;;/h3-8,13-16,18,35,40-41H,9-12,17,19-20H2,1-2H3,(H,33,43);2*1H

InChI key

OTFWXMFLPMUDFP-UHFFFAOYSA-N

Comparar elementos similares

Ver comparación completa

Mostrar Diferencias

1 of 4

Este artículo
PZ0305SML2417SML2698
assay

≥98% (HPLC)

assay

≥98% (HPLC)

assay

≥95% (HPLC)

assay

≥98% (HPLC)

storage temp.

2-8°C

storage temp.

room temp

storage temp.

room temp

storage temp.

2-8°C

storage condition

desiccated

storage condition

-

storage condition

desiccated

storage condition

desiccated

solubility

H2O: 2 mg/mL, clear

solubility

H2O: 5 mg/mL, clear (warmed)

solubility

DMSO: 2 mg/mL, clear

solubility

H2O: 2 mg/mL, clear

color

white to beige

color

white to beige

color

white to beige

color

white to beige

Biochem/physiol Actions

WAY-267464 is a non-peptide drug with a novel mechanism of action (MOA) to treat psychosis and schizophrenia.[1]
WAY-267464 is a non-peptide oxytocin receptor (OTR) agonist (EC50 = 61-881 nM; Ki = 58-978 nM) that, unlike oxytocin (OT), displays antagonist instead of agonist activity toward vasopressin V1a receptor/V1aR (IC50 = 613 nM; Ki = 27-113 nM). WAY-267464 exhibits OT-like anxiolytic effects in assays measuring both behavioral (33% increase in punished crossing by 10 mg/mL ip or 10 μg/mouse icv in four-plate tests; 75% increased open quadrants stay by 3 μg/mouse icv in elevated zero maze) and autonomic (47% higher stress-induced hyperthermia by 10 μg/mouse icv) parameters of the anxiety response. Similar to the antipsychotic-like effects reported for OT, WAY-267464 also reverses disruption in prepulse inhibition of the acoustic startle reflex induced by either MK-801 or amphetamine. Unlike OT, WAY-267464 does not affect immobility in mouse tail suspension test.

Storage Class

11 - Combustible Solids

wgk_germany

WGK 3

flash_point_f

Not applicable

flash_point_c

Not applicable


  • Elija entre una de las versiones más recientes:

    Certificados de análisis (COA)

    Lot/Batch Number

    Lo sentimos, en este momento no disponemos de COAs para este producto en línea.

    Si necesita más asistencia, póngase en contacto con Atención al cliente

    ¿Ya tiene este producto?

    Encuentre la documentación para los productos que ha comprado recientemente en la Biblioteca de documentos.

    Visite la Librería de documentos

    Yamei Tang et al.
    Neuropharmacology, 77, 277-284 (2013-10-24)
    Oxytocin (OT) was reported to affect cognitive and emotional behavior by action in ventral tegmental area (VTA) and other brain areas. However, it is still unclear how OT activates VTA and related midline nucleus. Here, using patch-clamp recording, we studied
    Robert L Gannon
    Brain research, 1585, 184-190 (2014-08-26)
    The synchronization of circadian rhythms in sleep, endocrine and metabolic functions with the environmental light cycle is essential for health, and dysfunction of this synchrony is thought to play a part in the development of many neurological disorders. There is
    Robert H Ring et al.
    Neuropharmacology, 58(1), 69-77 (2009-07-21)
    The widely reported effects of oxytocin (OT) on CNS function has generated considerable interest in the therapeutic potential for targeting this system for a variety of human psychiatric diseases, including anxiety disorders, autism, schizophrenia, and depression. The utility of synthetic
    C Hicks et al.
    British journal of pharmacology, 171(11), 2868-2887 (2014-03-20)
    There is current interest in oxytocin (OT) as a possible therapeutic in psychiatric disorders. However, the usefulness of OT may be constrained by peripheral autonomic effects, which may involve an action at both OT and vasopressin V1A receptors. Here, we
    William T Jorgensen et al.
    European journal of medicinal chemistry, 108, 730-740 (2016-01-08)
    A previously identified, non-peptidic oxytocin (OT) receptor agonist WAY-267,464 (1) and nine novel derivatives (3, 4a-7a, 4b-7b) were synthesised and evaluated in vitro with the aim of systematically exploring hydrogen bonding interactions and ligand flexibility. All analogues were subjected to competition

    Nuestro equipo de científicos tiene experiencia en todas las áreas de investigación: Ciencias de la vida, Ciencia de los materiales, Síntesis química, Cromatografía, Analítica y muchas otras.

    Póngase en contacto con el Servicio técnico